You searched for Cybin - Page 47 of 60

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial”

QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to … Continue reading “QualityStocksNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.”

QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that president and CEO Kelsey Ramsden will be participating in the Advances in Mental Health Virtual Conference. The one-day conference, presented by Maxim Group LLC and hosted by M-Vest, is scheduled for Sept. 22, … Continue reading “QualityStocksNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference”

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and … Continue reading “Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)”

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Participation in Oppenheimer Fall Healthcare Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, will be a featured presenter at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The three-day event, scheduled for Sept. 20–23, 2021, will be a virtual event. Tryp CEO and chair Greg McKee … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Participation in Oppenheimer Fall Healthcare Summit”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook

So far in 2021, Tryp’s innovations have allowed it to position itself as a first-mover in the psychedelics space The company has announced completion of psychotherapy training for the upcoming phase 2a clinical trials for specific overeating disorders Tryp has also been keen on collaborating and partnering with key players in the industry, such as … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), Innovation, Partnerships, and Leadership: A 2021 Outlook”

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview

Mind Cure Health Inc. CEO Kelsey Ramsden was featured in a recent Bell2Bell podcast interview, during which she explained the company’s primary focal points – digital therapeutics and drug development On the digital therapeutics side of its business, the company is developing iSTRYM, a clinical-grade, evidence-backed, science-based, AI-driven tool for both therapists and patients, scheduled … Continue reading “Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) CEO Discusses Psychedelics, Company’s Progress, Plans, Business in a Recent Bell2Bell Podcast Interview”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021 Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13 … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference”

QualityStocksNewsBreaks – Why Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is committed to bringing science-backed benefits to all and reframing the psychedelic conversation. “The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the ‎first psychedelic umbrella platform. It is currently a trusted source … Continue reading “QualityStocksNewsBreaks – Why Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Is ‘One to Watch’”

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders

Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Training for Upcoming Phase 2a Psychedelics Trial Targeting Eating Disorders”

Site Search

Company Search

Search Results for: Cybin